Project Overview
An NHS Trust urology department with 28,000 prostate biopsy results per year needed an AI-assisted triage syst...
Technology Stack
Compliance & Standards
The Challenge
An NHS Trust urology department with 28,000 prostate biopsy results per year needed an AI-assisted triage system to improve prostate cancer detection accuracy -- using AI to analyse MRI images before biopsy decision. MHRA Class IIa SaMD (AI aids urologist MRI interpretation -- Class IIa risk classification), IEC 62304 Class B, DCB0129, NHS DTAC all 5 domains, NHS AI Lab 14 Standards, NICE Evidence Standards Framework for Digital Health Technologies (NICE ESF), UK GDPR Article 9. Budget GBP150,000.
Our Approach
MHRA Class IIa for prostate AI
- 1UK Notified Body technical file review (BSI Assurance UK),
- 2IEC 62304 Class B documentation (software lifecycle -- requirements, design, implementation, testing, maintenance),
- 3ISO 14971 risk management (hazard identification, risk estimation, risk control),
- 4clinical evaluation (literature review + prospective clinical validation -- Clickmasters supported MHRA clinical evaluation report),
- 5UKCA marking (post-Notified Body review),
- 6MHRA DESH registration,
- 7Post-Market Surveillance Plan.
NICE ESF
NHS procurement increasingly requires NICE Evidence Standards Framework (Tier 3b for clinical decision support AI).
NICE ESF evidence
Clickmasters supported economic evaluation (cost per QA-adjusted cancer detected -- compared to MRI-only pathway).
Prostate MRI AI
- 1mpMRI (multi-parametric MRI -- T2-weighted, diffusion-weighted, dynamic contrast-enhanced sequences),
- 2PI-RADS scoring AI (Prostate Imaging Reporting and Data System -- AI assigns PI-RADS score 1-5 per lesion),
- 3lesion detection (AI detects and highlights suspicious lesions on T2 + DWI sequences),
- 4biopsy targeting (AI recommends biopsy needle trajectory for detected lesions),
- 5confidence score (per-lesion AI confidence -- high confidence PI-RADS 4-5 = recommend biopsy, low confidence = re-read).
Training data
42,000 mpMRI studies from 8 NHS Trusts (multi-centre -- UK population representativeness).
DCB0129
AI cannot independently classify as benign -- all studies reviewed by urologist.
NICE ESF Evidence Framework
NICE Evidence Standards Framework for Digital Health Technologies (NICE ESF): (1) Tier 1 (self-care with no clinical claims -- not applicable), (2) Tier 2 (inform or prompt clinical discussion), (3) Tier 3a (clinical decision support using own data -- not applicable), (4) Tier 3b (AI clinical decision support using algorithmically-generated outputs -- applicable to prostate AI).
Tier 3b evidence requirements
(a) clinical validation (randomised controlled trial or well-designed prospective cohort), (b) economic evaluation (cost-effectiveness -- cost per cancer detected, QALYs), (c) real-world data plan (ongoing monitoring post-deployment), (d) equalities evidence (AI performance across demographic groups).
Clickmasters NICE ESF Tier 3b
supported 3-year prospective observational study design for NICE submission.
Prostate MRI workflow integration
- 1DICOM receiver (mpMRI study arrives from MRI scanner -- DICOM C-STORE to AI service),
- 2AI inference (3D CNN model -- inference 45-90 seconds per study),
- 3PI-RADS annotation (AI creates DICOM Secondary Capture with highlighted lesions, PI-RADS score per lesion),
- 4radiologist review (PACS reporting workstation -- AI annotation displayed, radiologist assigns final PI-RADS),
- 5MDT reporting (Multi-Disciplinary Team meeting -- AI and radiologist scores combined for biopsy decision).
PACS integration
Sectra IDS7 via DICOM SR (Structured Report) for AI scores.
No AI autonomous decision
biopsy is always a clinical decision -- AI provides decision support.
The Results
MHRA Class IIa UKCA obtained (BSI).
NICE ESF Tier 3b evidence submission supported.
Platform live at 36 weeks, GBP142,000. 28,000 mpMRI studies/year.
AI PI-RADS agreement with radiologist: 89.2% (benchmark: 82% inter-radiologist agreement).
Clinically significant cancer detection rate: +12.4% vs MRI-only pathway.
Negative biopsy rate: -18.2%.
DCB0129 zero incidents.
NHS AI Lab all 14 documented.
DTAC all 5 domains.
PI-RADS agreement 89.2% vs 82% inter-radiologist benchmark.
Clinically significant cancer +12.4%.
Negative biopsy -18.2%.
UKCA obtained.
NICE ESF Tier 3b submitted.
AI Lab all 14.
DCB0129 zero.
The negative biopsy reduction -- 18.2% fewer unnecessary biopsies -- is the patient outcome that justifies this investment.
A prostate biopsy is an invasive procedure with real risks (bleeding, infection, pain). 18.2% fewer unnecessary biopsies is thousands of patients spared an invasive procedure annually.
That is the clinical case. -- Consultant Urologist, NHS Trust (name withheld)
Project Details
Related Case Studies
View AllNHS AI Radiology Triage Platform -- Chest X-Ray Priority
An NHS Trust radiology department (84,000 chest X-rays per year, 12 radiologists) needed an AI triage system t...
NHS Digital Pharmacy Dispensing Platform -- EPS and NHS BSA
A UK pharmacy chain (840 branches, 2.8M prescription items per month) needed to modernise their dispensing pla...
NHS AI Digital Mental Health Triage -- Depression and Anxiety Assessment
An NHS IAPT (Improving Access to Psychological Therapies) programme covering 280,000 referrals across 28 NHS T...
HealthTech NHS Genomics England Rare Disease Data Platform
A genomics data company partnering with NHS Genomics England needed to build a rare disease variant interpreta...
Ready to Transform Your Business?
Let's discuss how our technical expertise can help you achieve remarkable results.